• Biosimilars Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Biosimilars Market Forecast including Production, Consumption, Import and Export Forecast by
Type, Applications and Region.
• Research Findings and Conclusion
Increasing number of biosimilar approvals is expected to drive the growth of biosimilars market
Increase in number of approved biosimilars due to greater clarity in the U.S. Food and Drug
Administration (FDA) review process other than manufacturing and development process are
expected to drive biosimilars market growth. For instance, in July 2018, the U.S. FDA
introduced a Biosimilars Action Plan to encourage the development of biosimilars. This approval
process encourages applicants to resolve patent disputes before launch of biosimilars.
Moreover, the number of filed biosimilars applications has increased as manufacturers have
become more comfortable with the complex regulatory and litigation schemes associated with
filing a biosimilar application. For instance, since 2015, the U.S. FDA has approved 16
biosimilars and the number is expected to increase over the forecast period. Several other
government agencies are also following similar trends for product approvals. For instance, in
November 2017, Samsung Bioepis received two approval for its adalimumab biosimilar, Hadlima
(SB5) and for its trastuzumab biosimilar, Samfenet (SB3), from the Korean Ministry of Food and
Drug Safety (South Korea).
Market Dynamics
Increasing number of biosimilar approvals in clinical management of various diseases such as
diabetes and hormonal imbalance is expected to drive growth of the biosimilars market.
According to the Generics and Biosimilars Initiative (GABI) 2017 report, around 40 different
biosimilars were approved in Europe, covering several different therapeutic classes: granulocyte
colony-stimulating factors, and erythropoiesis-stimulating agents (ESAs), among others.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/750